Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Alberto Martinez-Vea"'
Autor:
Intza Garin, Víctor Martínez, Alberto Martinez-Vea, Mario Espinosa, Oliver Valero, José Ballarín, Miguel A. Garcia-Gonzalez, Elisabet Ars, David Arroyo, Gemma Bullich, Patricia Ruiz, Nadia Ayasreh, Xavier Fulladosa, Roser Torra, Laura Lorente, Mónica Furlano, Rosa Miquel, Vanessa Pérez-Gómez, Nisrine Arhda
Publikováno v:
American Journal of Kidney Diseases. 72:411-418
Rationale & Objective Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a rare underdiagnosed cause of end-stage renal disease (ESRD). ADTKD is caused by mutations in at least 4 different genes: MUC1, UMOD, HNF1B, and REN. Study Design
Autor:
Ana Molina Ramos, Carmen A. Peralta, Carmen García, J. A. Oliver, Esther Salvadó, Amadeo Saurí, Montse Broch, Teresa Compte, Cristina Gutierrez, Alberto Martinez-Vea, Pere Angelet, Alfredo Bardají, R Pastor, Luis Marcas
Publikováno v:
American Journal of Kidney Diseases. 47:241-250
Background: Silent cerebral white matter lesions are observed on magnetic resonance imaging (MRI) scans in elderly people, and they are related to vascular risk factors, particularly hypertension. No data on the prevalence and risk factors of white m
Autor:
C. Garcia-Ruiz, M. Olona, A. Oliver, Carmen A. Peralta, A. Sauri, T. Sempere, Alberto Martinez-Vea
Publikováno v:
Clinical Nephrology. 61:170-176
Background: Spiral computed tomography angiography (CTA) is a sensitive and specific technique for visualizing renal arteries and diagnosing renal artery stenosis (RAS). Whether spiral CTA is associated with increased risk of contrast nephropathy (CN
Autor:
Ramón Font Font, Marta Romeu, Montserrat Giralt, Carmen Cabré, Carmen García, Manel Jariod, Alberto Martinez-Vea, Mercedes Prats, Mònica Muñoz-Cortés
Publikováno v:
Clinical nephrology. 81(6)
Nearly half of all non-dialysis chronic kidney disease (CKD) patients respond to iron therapy. Factors affecting anemia response to iron therapy are not well characterized. Oxidative stress (OS) is a recognized factor for anemia in CKD and promotes e
Autor:
Cristina Gutierrez, Alfredo Bardají, Montserrat Broch, J. A. Oliver, F.A. Valero, Cristóbal Richart, Carmen García, Alberto Martinez-Vea
Publikováno v:
Scopus-Elsevier
Left ventricular hypertrophy (LVH) is a common finding in hypertensive autosomal dominant polycystic kidney disease (ADPKD) patients. There are few studies on the influence of blood pressure (BP) and nonhemodynamic factors on LVH in these patients. T
Publikováno v:
Journal of Electrocardiology. 32:45-49
Severe hyperkalemia with minimal or nonspecific electrocardiographic (ECG) changes is unusual. We report data on seven patients with renal failure, metabolic acidosis, and severe hyperkalemia (K+ > or =8 mmol/L) without typical ECG changes. Initial E
Autor:
Maria Vinaixa, Marta Romeu, Núria Amigó, Carmen Cabré, Mònica Muñoz, Montse Giralt, Alberto Martinez-Vea, Rocio Fuertes, Xavier Correig, Jordi Vallespir Soler, Maria Teresa Compte, Josep Aguilera
Publikováno v:
Nephrology Dialysis Transplantation. 31:i251-i251
Autor:
Marta Romeu, Carmen A. Peralta, Carmen García, Alfredo Bardají, Alberto Martinez-Vea, Teresa Compte, Luis Marcas, Rosa Nogues, Montserrat Giralt, Cristina Gutierrez
Publikováno v:
Clinical nephrology. 77(3)
Oxidative stress (OS) is involved in left ventricular hypertrophy (LVH). Short-term treatment with erythropoietin (EPO) in chronic kidney disease (CKD) complicated by anemia and LVH is associated with a reduction in left ventricular mass (LVM). We pr
Autor:
Cristina Gutierrez, Alfredo Bardají, Merche Prats, Ramon Font, Marta Lalana, Alberto Martinez-Vea, Angels Vilanova
Publikováno v:
Blood pressure. 19(1)
Cystatin C is a marker of kidney function and a predictor of cardiovascular morbidity and mortality. It is unknown whether this protein may be related to the cardiac involvement that is common among patients with essential hypertension.We evaluated t
Autor:
Alfredo Bardají, Carmen García, Cristóbal Richart, Jesús Angel Oliver, Alberto Martinez-Vea, Cristóbal Ridao
Publikováno v:
American Journal of Kidney Diseases. 19:353-357
Long-term myocardial effects of recombinant human erythropoietin (rhEPO) therapy were investigated in nine hemodialysis (HD) patients greater than 60 years of age. Echocardiographic studies were performed before the administration of rhEPO with a hem